Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

a technology of sgk1 activity and autoimmune disorders, which is applied in the direction of enzyme inhibitor ingredients, antibody medical ingredients, peptide/protein ingredients, etc., can solve the problems of autoimmune disease or cancer patients, patients who have received organ transplants, and are susceptible to infections, so as to enhance the th1-mediated immune response in the subject, the effect of enhancing the th1-mediated immune respons

Inactive Publication Date: 2014-05-01
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a method for enhancing the immune response in a person by giving them a medication that inhibits a specific protein called serum-glucocorticoid regulated kinase-1 (SGK1). This medication is meant to increase the person's ability to fight infections and help them better respond to vaccinations. The method involves giving the medication to the person before or after they receive the vaccine.

Problems solved by technology

As such, patients being treated for autoimmune disease or cancer or who have received organ transplants are susceptible to infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
  • Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
  • Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0073]In an effort to determine the mechanism by which mTOR regulates T cell fate, mice were generated in which SGK1 was selectively deleted in T cells. SGK1 floxed mice (A. Fejes-Toth) were bred to CD4-Cre mice, leading to the deletion of SGK1 in T cells, hereafter referred to as T-SGK1− / − mice (FIG. 2). Naïve T cells from Wt, T-Rictor− / − and T-SGK1− / − mice were stimulated with anti-CD3 anti-CD28 and immunoblotted to assay for activity of TORC1 and TORC2 substrates upon TCR engagement (FIG. 3A). Upon stimulation, Wt CD4+ T cells display enhanced mTORC2 activity, as measured by phosphorylation of Akt at serine 473. A selective defect in Akt S473 phosphorylation was observed in T-Rictor− / − mice, which completely lack mTORC2 activity, but this decrease in Akt activity was not observed in T-SGK1− / − mice, indicating that SGK1 functions in a pathway that is downstream of TORC2, yet parallel to Akt. It was previously shown by the inventors that loss of mTORC2 promotes hyperactivation of m...

example 2

[0075]Determination of the functional consequences of deleting SGK1 in CD4+ T cells. Unlike T-Rictor− / − mice, which have a normal lymphocyte compartment, fewer CD3+ T cells were observed in the spleen and lymph nodes of T-SGK1− / − mice (FIGS. 4, 5). Furthermore, T-SGK1− / − mice had a reduced ratio of CD4+ relative to CD8+ T cells in peripheral lymphoid organs. Despite this reduction in the percentages of T cells, T-SGK1− / − mice have similar percentages of natural regulatory T cells and IL-17 producing CD4+ cells in Peyer's patches of the small intestine (FIGS. 6, 7). In addition to their reduced number of T cells, it was also found that CD4+ T cells from T-SGK1− / − mice displayed a slightly reduced rate of proliferation when stimulated with anti-CD3 and irradiated autologous antigen presenting cells (APCs) (FIG. 8). Despite their reduced proliferation, it was found that CD4+ T cells from T-SGK1− / − mice displayed robust cytokine production.

[0076]Like T-Rictor− / − mice, T-SGK1− / − mice con...

example 3

[0077]The determination of the biochemical mechanism by which SGK1 reciprocally regulates Th1 and Th2 differentiation. The inventors have previously shown that CD4+ T cells from T-Rictor− / − mice show diminished phosphorylation of STAT6 in response to IL-4. However, when CD4+ T cells from T-SGK1− / − mice were treated with IL-4, phosphorylation of STAT6 at tyrosine 641 was observed (FIG. 10), suggesting that SGK1 was regulating Th2 differentiation via some other mechanism. Previous studies on the role of SGK1 in renal epithelial cells have demonstrated that SGK1 negatively regulates the HECT-type E3 ligase neural precursor cell expressed, developmentally down-regulated gene 4-like (NEDD4L) by phosphorylation at serine 342 and serine 448. A closely related homolog of NEDD4L is the ubiquitin ligase Itch, which has been shown to interact with the Nedd4 family-interacting protein 1 (Ndfip1) adapter protein to mediate polyubiquitination of JunB, a transcription factor that is essential for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
massaaaaaaaaaa
biological stabilityaaaaaaaaaa
physical stabilityaaaaaaaaaa
Login to View More

Abstract

The present invention provides novel methods for treating Th2-mediated immune disorders and enhancing Th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (SGK1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught. The present invention also provides methods for augmenting the treatment of subjects having viral or parasitic infections, or which have cancerous tumors.

Description

REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Patent Application No. 61 / 487,783, filed on May 19, 2011, which is hereby incorporated by reference for all purposes as if fully set forth herein.STATEMENT OF GOVERNMENTAL INTEREST[0002]This invention was made with U.S. government support under grant no. RO1AI077610. The U.S. government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]The mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine-threonine kinase that integrates multiple environmental signals to regulate cell metabolism, proliferation, and survival. In the immune system, mTOR is emerging as a critical integrator of signals from the immune microenvironment leading to T helper cell differentiation and function, APC differentiation and function, and CD8+ T cell memory and effector generation. Our laboratory has shown that mTOR can associate with two distinct protein complexes (mTORC1 and mT...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K38/00A61K31/7088A61K38/02A61K31/437A61K31/713
CPCA61K39/3955A61K31/437A61K31/7088A61K31/713A61K38/005A61K38/02A61K31/4439A61P11/06A61P17/14Y02A50/30
Inventor POWELL, JONATHAN DAVIDHEIKAMP, EMILY BETH
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE